Qvar Inhaler

Quick links to important sections

Qvar Inhaler

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Qvar Inhaler

Quick Facts

Property Description
Active ingredient Beclomethasone dipropionate
Form Pressurized Metered-Dose Inhaler (MDI) / Aerosol
Pharmacological class Inhaled Corticosteroid (ICS) / Glucocorticoid
Common role Prophylactic asthma maintenance
Origin Synthetic derivative

What Type of Medicine is Qvar Inhaler and How is it Classified?

Qvar Inhaler is a prescription-only medicine whose primary role is the long-term, maintenance treatment of asthma in patients four years of age and older. It belongs to the pharmacological class of Inhaled Corticosteroids (ICS), which are recognized for their potent anti-inflammatory properties. This defines Qvar as a preventer medicine used regularly to manage the underlying disease. Unlike fast-acting rescue inhalers used for sudden, acute shortness of breath, Qvar is specifically not indicated for the relief of acute bronchospasm.

Composition, Form, and Unique Features

The single active ingredient in this inhalation preparation is Beclomethasone dipropionate (BDP), a synthetic corticosteroid derivative. The product is unique in its delivery system and composition: it is formulated as an extrafine particle aerosol solution with a hydrofluoroalkane (HFA) propellant. The successful development of this extrafine particle size is clinically recognized for allowing an effective concentration of the medicine to reach both the large and small airways.

Qvar Inhaler’s General Purpose and Role in Asthma Care

The general therapeutic purpose of this ICS medicine is to control asthma by addressing the chronic inflammation and airway hyperresponsiveness that characterizes the condition. Its action is locally focused on the lung tissue, suppressing the activity of inflammatory cells. Inhaled corticosteroids are used for maintenance therapy in chronic asthma. The primary benefit of this daily maintenance therapy is achieving sustained control over the asthmatic condition, thus helping to normalize lung function and significantly reduce the frequency and severity of future exacerbations.

What side effects are possible with Qvar Inhaler?

Possible side effects and safety information

The safety profile of Qvar Inhaler (beclomethasone dipropionate) is defined by officially documented adverse reactions categorized by frequency and the affected body system, as established in regulatory documents from bodies like the FDA and EMA.

Adverse effects are broadly classified into local reactions and potential systemic effects related to its corticosteroid nature. The most commonly reported reactions are generally localized to the respiratory and nervous systems.


Official Adverse Reaction Frequencies

Classification Examples of Documented Adverse Reactions
Most Common / Very Common Headache, Upper Respiratory Tract Infection
Common Oropharyngeal Candidiasis (Oral Thrush), Pharyngitis, Dysphonia, Nasopharyngitis
Uncommon / Rare Skin rash, Urticaria
Very Rare Paradoxical Bronchospasm, Anaphylactic Reaction, Angioedema

Serious Adverse Reactions and Safety Constraints

Regulatory documentation highlights serious adverse reactions that are rare but clinically significant. These include Paradoxical Bronchospasm, which may occur immediately following administration, and Adrenal Suppression, a potential systemic effect of glucocorticoids, particularly when transferring from oral corticosteroids. Growth retardation is a documented safety concern for pediatric patients, necessitating routine monitoring of growth rate.

The medicine is formally contraindicated for the primary treatment of status asthmaticus or acute episodes of asthma. Long-term use is associated with the potential for systemic effects on the Eye Disorders system, including the development of Cataracts and Glaucoma. The regulatory safety information stresses that caution is warranted in patients using strong CYP3A inhibitors due to the possibility of increased systemic exposure.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Qvar Inhaler (beclomethasone dipropionate) is primarily associated with chronic use of higher than recommended dosages, which may lead to systemic corticosteroid effects. The documented physiological manifestations involve the Hypothalamic-Pituitary-Adrenal (HPA) axis, potentially resulting in hypercorticism or adrenal suppression (reduced adrenal function). In pediatric patients, this HPA axis depression is also linked to a risk of growth retardation.

Required Emergency Actions

If signs of hypercorticism or adrenal suppression occur, regulatory guidance states that the Qvar dose should be reduced slowly, consistent with established clinical procedures for weaning off systemic corticosteroids. Patients who may have been using too much of the inhaler for a long duration are advised to contact a healthcare provider, or a Poisons Information Centre, even if no immediate signs of discomfort or poisoning are present.

When to Seek Immediate Medical Attention

Immediate emergency medical help is required right away if signs or symptoms of a serious allergic reaction occur. These severe reactions may include hives, swelling of the lips, tongue, or face (angioedema), rash, or breathing problems (bronchospasm).

Urgent medical review of therapy is also required if asthma symptoms worsen, if a short-acting rescue inhaler becomes less effective, or if more inhalations than usual are needed to achieve symptom relief.

Therapeutic Uses of Qvar Inhaler

What Qvar Inhaler Treats: Main Uses and Benefits

The Qvar Inhaler may be part of symptomatic management for conditions involving episodic or fluctuating manifestations, such as asthma. This medication is commonly used to help with symptoms related to inflammatory or irritative states within the breathing tubes. This long-term approach is considered relevant for managing symptoms associated with asthma.

It is applied in addressing symptom clusters that may become intense or disruptive, such as symptoms related to heightened physiological activity, including wheezing, coughing, and chest tightness. By assisting with the management of these chronic manifestations, it supports the patient during difficult symptomatic phases.

This supportive relief contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability, particularly during routine activities.


Regular use supports patients during conditions involving episodic or fluctuating manifestations.


Quick Fact:
Supports management of symptoms that interfere with daily functioning

Regulatory References

  1. DailyMed NIH official prescribing information

Eligibility and Restrictions for Use

Who Can and Cannot Use Qvar Inhaler?

This information reflects the official eligibility profile of Qvar Inhaler (beclomethasone dipropionate) as documented by regulatory agencies.


Contraindications (Who Must Not Use Qvar)

Qvar is contraindicated (must not be used) in the following situations, as stated in the product label:

  • Hypersensitivity: Individuals with a known allergy or severe hypersensitivity to beclomethasone dipropionate or any other ingredient in the product.
  • Acute Asthma: It is contraindicated for the primary treatment of status asthmaticus or any other acute episode of asthma. Qvar is a maintenance medication, not a rescue inhaler.

Eligibility by Age and Condition

Category Regulatory Eligibility Rule
Minimum Age Use is typically authorized for patients 4 years of age and older (Qvar RediHaler) or 5 years of age and older (Qvar Inhaler), depending on the specific product formulation and jurisdiction. Safety and efficacy are not established in younger children.
Infections Use with caution in patients with active or quiescent tuberculosis or any untreated systemic infection (fungal, bacterial, parasitic, or viral).
Pregnancy/Lactation Use during pregnancy should only be considered if the potential benefit justifies the potential risk. No adequate data exist on its presence in human milk, though systemic exposure is typically low.
Systemic Steroid Transfer Patients transferring from oral (systemic) corticosteroids require special supervision due to the risk of adrenal insufficiency.

This information is for regulatory reference only and does not substitute for clinical advice.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Qvar Inhaler (beclomethasone dipropionate) is an inhaled corticosteroid, and its active components have the potential for systemic effects that can lead to drug interactions. The primary interaction risk involves concurrent use with potent CYP 450 enzyme inhibitors, such as certain antifungal or antiviral agents (e.g., protease inhibitors). These medicines can slow the metabolism of beclomethasone's active metabolite, which may increase the systemic exposure of the corticosteroid and heighten the risk for adverse effects like hypercorticism or adrenal suppression.

Other Significant Interactions

Interaction Type Interacting Products/Classes Regulatory Context
Increased Toxicity/Risk Other immunosuppressants Combined use may increase the risk of infection or overall toxicity.
Decreased Effect Live Vaccines (e.g., BCG) Corticosteroids may interfere with the patient's immune response, reducing the vaccine's efficacy.
Avoid Combination Desmopressin, Mifepristone Specific medicines noted in official sources where concurrent use is not recommended.

Important Interaction-Related Notes

Care is required when transferring patients from chronic oral systemic corticosteroids to this inhaled product, as insufficient adrenal function may persist, requiring careful tapering of the systemic steroid. Due to its potential for immunosuppression, the inhaler should be used with caution in patients with active or quiescent tuberculosis, or untreated systemic fungal, bacterial, parasitic, or viral infections, including ocular herpes simplex.

Mechanism of Action

Glucocorticoid Receptor Activation

The active metabolite of Qvar, beclomethasone-17-monopropionate (B-17-MP), acts as an agonist for glucocorticoid receptors (GRs) found within inflammatory and structural cells of the airways. This drug-receptor complex translocates into the cell nucleus, initiating genomic modulation.


Suppression of Inflammatory Cascades

The genomic modulation primarily involves transrepression, which suppresses genes that encode pro-inflammatory mediators such as cytokines, chemokines, and inflammatory enzymes. This pathway modulation results in the restriction of subsequent downstream effects, including the diminished recruitment and activation of immune cells (such as eosinophils and T-lymphocytes) into the subepithelial space.


Modulation of Airway Mechanistic Effects

By limiting these initial molecular steps, the drug's mechanism contributes to a reduction in inflammatory cellular load and swelling within the airway wall. This assists in creating a more regulated state within targeted pathways, ultimately modulating the processes that influence the physiological characteristic of hyper-responsiveness.

Dosage and Administration Information

This section details the administration protocol for Qvar Inhaler (Beclomethasone dipropionate HFA). The medicine is strictly for oral inhalation and is intended for regular, long-term maintenance use, not for the relief of sudden, acute symptoms.


Dosing and Frequency

Feature Guideline
Route of Administration Oral inhalation only.
Dosing Schedule Dosing is typically twice daily (BID), with administrations spaced approximately 12 hours apart.
Adult Starting Dose Generally 40 mu g to 80 mu g twice daily.
Adult Maximum Dose The maximum recommended daily administration is generally 320 mu g twice daily.
Pediatric Dosing (4–11 years) Starting dose is 40 mu g twice daily, with a maximum typically limited to 80 mu g twice daily.

Administration Protocol

Therapy is intended to be continuous, and the full effect may require 3 to 4 weeks to be fully realized. The dosage may be titrated (adjusted) upward if the response is inadequate or downward once control is stable. If a dose is missed, patients should take the next dose at the regularly scheduled time and should not take a double dose to compensate.

Following each administration, the protocol involves rinsing the mouth with water and spitting it out. For specific versions, such as the QVAR RediHaler, the device does not require shaking before use and is not intended for use with a spacer. The device must be discarded when the dose counter reaches zero.

Recent Clinical Evidence

Research evidence / Overview of Studies for Qvar Inhaler


Evidence for Maintenance Treatment of Persistent Asthma

Research into Qvar Inhaler was evaluated in Randomized Controlled Trials (RCTs) for asthma maintenance. These studies compared the medicine against a placebo or other existing therapies in diverse groups, including adults, adolescents, and children (typically aged four years and older).

Researchers monitored outcomes related to pulmonary function, such as forced expiratory volume in one second (FEV1), as well as tracking data points in asthma symptom scores and data points for rescue medication use. Multiple regulatory studies have described the patterns observed in the recorded measurements of lung function.

Studies Investigating Systemic Corticosteroid Dependence

A specific category of research was studied for inhaled beclomethasone dipropionate in patients with chronic, severe asthma who require maintenance treatment with oral steroid pills (OCS). The main aim of this research was to explore the OCS dose data points (reduction or discontinuation) while simultaneously monitoring recorded lung function measurements.

Studies documented the percentage of patients where a reduction in OCS dose was observed during the trial period. However, the sample sizes were modest for these specific studies, which means the data for certain groups remain insufficient. The results apply only to the populations studied and do not generalize to the wider asthma population.

Comparative Research and Limitations

Comparative research examines the body of trials investigating Qvar’s extrafine particle formulation against other inhaled corticosteroid (ICS) products. Findings describe patterns related to the required nominal dose of the medicine in studies comparing the extrafine version to older, larger-particle formulations.

Most foundational regulatory evidence is derived from trials with follow-up durations that were limited, often lasting only a few months. Long-term observational studies were used to examine data related to the maintenance of asthma control over time, but long-term effects are not fully established across all potential subgroups. The controlled nature of RCTs may not fully reflect effectiveness in observational settings evaluating daily-life functioning where adherence varies greatly.

Frequently Asked Questions (FAQ)

Common questions about Qvar Inhaler (FAQ)

Q: How quickly should I expect to notice a change after starting Qvar Inhaler?

A: Qvar Inhaler is a maintenance medication, and its full effects take time to develop. Official product information indicates that improvements in lung function are generally apparent within one to four weeks after starting therapy. It is not intended for immediate relief of sudden symptoms.


Q: What happens if I accidentally swallow some of the Qvar Inhaler mist?

A: Official instructions require rinsing the mouth with water and spitting it out after using the inhaler. This protocol is intended to help reduce the risk of localized infections, such as oral thrush. While the medication is designed to have low systemic exposure at therapeutic doses, this rinsing step is described in the official administration protocol.


Q: If I miss a dose of Qvar Inhaler, what is the best thing to do?

A: The official administration protocol advises that if a dose is missed, patients should take the next dose at the regularly scheduled time. The protocol specifies that a double dose should not be taken to compensate for a missed dose.


Q: Can using Qvar Inhaler make me more susceptible to infections?

A: Regulatory safety information notes that patients using corticosteroids, which are drugs that suppress the immune system, are more susceptible to certain infections. The official label notes that caution is warranted in patients with existing systemic infections (e.g., tuberculosis or viral conditions).


Q: Can Qvar Inhaler affect my vision?

A: Regulatory documents indicate that long-term use of inhaled corticosteroids may be associated with the potential for systemic effects on the eyes. This includes the possibility of developing cataracts and glaucoma.


Q: Does Qvar Inhaler have a strong effect on the rest of the body, or just the lungs?

A: The medicine is specifically formulated as an extrafine particle aerosol so that its action is primarily focused locally on lung tissue to control inflammation. However, regulatory documentation notes the potential for systemic effects of this corticosteroid, which include the possibility of adrenal suppression, particularly at higher than recommended doses.


Q: Are there any warnings about Qvar Inhaler use and glaucoma?

A: Glaucoma is listed in the official safety documentation as a potential serious adverse reaction associated with the long-term use of inhaled corticosteroids. This is noted under the systemic effects of the medication.


Q: How long does the medication in Qvar Inhaler last once the canister is opened?

A: The official disposal instructions describe discarding the inhaler when the dose counter reads zero or after the expiration date printed on the label, whichever occurs first.


Q: Can Qvar Inhaler cause weight gain?

A: Regulatory documentation notes the rare potential for systemic corticosteroid effects, such as Hypercorticism or Cushingoid features. These effects are typically associated with increased exposure and may involve changes in body composition.


Q: Is it true that Qvar Inhaler can cause hoarseness or a sore throat?

A: Yes, official regulatory documents list Pharyngitis (sore throat) and Dysphonia (hoarseness) as common adverse reactions associated with Qvar Inhaler use.


Q: Does Qvar Inhaler interact with cold and flu medicine?

A: Patients are instructed in official guides to tell their healthcare provider about all medicines they take, including both prescription and over-the-counter medicines.


Q: Can Qvar Inhaler affect my ability to drive or operate machinery?

A: Regulatory documents list uncommon nervous system adverse reactions, including reports of tremor or vertigo (a type of dizziness). Official documents list these reactions under nervous system disorders.


Q: Is Qvar Inhaler safe to use during pregnancy?

A: The official regulatory stance states that use during pregnancy should only be considered if the potential benefit is thought to justify the potential risks. Available human data do not establish the presence or absence of drug-associated risk to the fetus.


Q: Are there any specific foods or drinks I should avoid while using Qvar Inhaler?

A: Official information does not specify any particular foods or non-alcoholic drinks to avoid. However, the medicine is noted to contain a small amount of ethanol (alcohol) as an inactive ingredient, though regulatory documents state this small amount will not have any noticeable effects.


Q: Can Qvar Inhaler be used for conditions other than asthma?

A: Qvar Inhaler is formally indicated for the long-term maintenance treatment of asthma in patients who are four years of age or older. Official product information does not list indications for other conditions.


Q: Does Qvar Inhaler affect blood sugar levels?

A: Studies have examined the effects of inhaled corticosteroids on blood glucose. Some research has documented a rise in peak blood glucose concentration following a glucose challenge in normal subjects using high doses of inhaled beclomethasone dipropionate.


Q: Is it common to feel jittery or shaky after using Qvar Inhaler?

A: Jitteriness or shakiness falls under the category of tremor. Regulatory documentation lists tremor as an uncommon adverse reaction related to nervous system disorders.


Q: Does Qvar Inhaler contain lactose or any common allergens?

A: The active ingredient is beclomethasone dipropionate, formulated with the propellant HFA-134a and ethanol. The product is formally contraindicated for those with a known allergy or severe hypersensitivity to beclomethasone dipropionate or any other ingredient in the product.


Q: What is the risk of osteoporosis associated with Qvar Inhaler?

A: The long-term administration of inhaled corticosteroids has been associated with the potential for decreases in bone mineral density (osteopenia) and the potential for osteoporosis. Official documents state that patients with risk factors for decreased bone mass are to be monitored.


Q: How does the beclomethasone in Qvar get absorbed into the body?

A: The medicine is specifically designed as an extrafine particle aerosol solution. This fine particle size helps the medicine reach both the large and small airways for localized action. This formulation is intended to allow for effective local concentration while resulting in low systemic exposure at therapeutic doses.


Q: Does Qvar Inhaler interact with non-prescription supplements like vitamins or herbs?

A: Official guidance advises patients to tell their healthcare provider about all of the medications they take. This includes all prescription and over-the-counter medicines, as well as vitamins and herbal supplements, to check for potential interactions.


Q: What is the total number of doses in a Qvar Inhaler canister?

A: The total number of doses depends on the specific product and strength prescribed. However, canisters typically provide either 100 or 120 inhalations, a count that is displayed on the dose counter.


Q: Does Qvar Inhaler cause thinning of the skin?

A: Thinning and bruising of the skin have been reported as potential systemic adverse effects related to the chronic use of inhaled corticosteroids.


How should Qvar Inhaler be stored and disposed of?

Storage and Disposal Requirements

The QVAR Inhaler (beclomethasone dipropionate HFA) must be stored under controlled conditions to maintain the integrity of its pressurized canister, as defined by regulatory labeling.


Storage Conditions

Requirement Details
Temperature Store at controlled room temperature, between 20 C and 25 C (68 F and 77 F). Do not expose the canister to temperatures above 49 C (120 F) or allow it to freeze.
Protection Keep the inhaler protected from direct light, heat, and open flame. For the QVAR RediHaler, the white cap must be kept closed during storage.
Safety The product must be stored out of the sight and reach of children.

Disposal Instructions

Condition Action
Discard When When the dose counter reads 0 or after the expiration date on the label, whichever occurs first.
Canister Handling Do not puncture the canister. Do not dispose of the canister in a fire or incinerator, even when empty. Consult a pharmacist for instructions on disposing of unused medication.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Qvar Inhaler found in:

A-Z Index: